Center for Pregnant Women with Diabetes, Rigshospitalet, Faculty of Health Sciences, Copenhagen, Denmark.
Diabetes Care. 2009 Jan;32(1):38-44. doi: 10.2337/dc08-1526. Epub 2008 Oct 22.
To describe pregnancy outcome in type 1 diabetic women with normoalbuminuria, microalbuminuria, or diabetic nephropathy after implementation of an intensified antihypertensive therapeutic strategy.
Prospective study of 117 pregnant women with type 1 diabetes. Antihypertensive therapy, mainly methyldopa, was given to obtain blood pressure <135/85 mmHg and urinary albumin excretion <300 mg/24 h. Blood pressure and A1C were recorded during pregnancy. The pregnancy outcome was compared with recently published studies of pregnant women with microalbuminuria or diabetic nephropathy.
Antihypertensive therapy was given in 14 of 100 women with normoalbuminuria, 5 of 10 women with microalbuminuria, and all 7 women with diabetic nephropathy. Mean systolic blood pressure during pregnancy was 120 mmHg (range 101-147), 122 mmHg (116-135), and 135 mmHg (111-145) in women with normoalbuminuria, microalbuminuria, and diabetic nephropathy, respectively (P = 0.0095). No differences in mean diastolic blood pressure or A1C were detected between the groups. No women with microalbuminuria developed preeclampsia. The frequency of preterm delivery was 20% in women with normoalbuminuria and microalbuminuria in contrast to 71% in women with diabetic nephropathy (P < 0.01) where the median gestational age was 258 days (220-260). Compared with previous studies using less stringent antihypertensive therapeutic strategy and less strict metabolic control, gestational age was longer and birth weight was larger in our study.
With intensified antihypertensive therapy and strict metabolic control, comparable pregnancy outcome was seen in type 1 diabetic women with microalbuminuria and normoalbuminuria. Although less severe than in previous studies, diabetic nephropathy was associated with more adverse pregnancy outcome.
描述在强化降压治疗策略实施后,伴有正常白蛋白尿、微量白蛋白尿或糖尿病肾病的 1 型糖尿病女性的妊娠结局。
对 117 例 1 型糖尿病孕妇进行前瞻性研究。主要使用甲基多巴进行降压治疗,以获得血压<135/85mmHg 和尿白蛋白排泄量<300mg/24h。在整个妊娠期间记录血压和 A1C。将妊娠结局与最近发表的伴有微量白蛋白尿或糖尿病肾病的孕妇研究进行比较。
在 100 例正常白蛋白尿孕妇中,14 例接受了降压治疗;在 10 例微量白蛋白尿孕妇中,5 例接受了降压治疗;在 7 例糖尿病肾病孕妇中,所有孕妇均接受了降压治疗。正常白蛋白尿、微量白蛋白尿和糖尿病肾病孕妇的妊娠期间平均收缩压分别为 120mmHg(范围 101-147mmHg)、122mmHg(116-135mmHg)和 135mmHg(111-145mmHg)(P=0.0095)。各组间平均舒张压或 A1C 无差异。微量白蛋白尿孕妇无一例发生子痫前期。正常白蛋白尿和微量白蛋白尿孕妇的早产率为 20%,而糖尿病肾病孕妇为 71%(P<0.01),糖尿病肾病孕妇的中位孕龄为 258 天(220-260 天)。与使用较不严格的降压治疗策略和较不严格的代谢控制的先前研究相比,本研究中妊娠年龄较长,出生体重较大。
通过强化降压治疗和严格代谢控制,伴有微量白蛋白尿和正常白蛋白尿的 1 型糖尿病女性的妊娠结局相似。虽然与先前的研究相比,糖尿病肾病的严重程度较轻,但与更不利的妊娠结局相关。